BridgeBio Pharma (BBIO) shares ended the last trading session 17.1% higher at $63.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 8.4% gain over the past four weeks.The stock rallied after the company announced positive top-line data from the pivotal phase III FORTIFY study evaluating BBP-418 in people living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The study achieved all primary and secondar ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Supernus Pharmaceuticals (SUPN) , which belongs to the Zacks Medical - Generic Drugs industry, could be a great candidate to consider.When looking at the last two reports, this drugmaker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 52.07%, on average, in the last two quarters.For the last reported q ...

Company Overview - Personalis (PSNL) shares increased by 20.5% to $10.28 in the last trading session, with a notable trading volume, and have gained 48.9% over the past four weeks [1][2] - The company specializes in contract research and genomic information, and is part of the Zacks Medical - Generic Drugs industry [4] Recent Developments - The surge in share price is attributed to new data from AstraZeneca's late-stage lung cancer study (LAURA), which utilized Personalis' NeXT Personal molecular residual disease (MRD) test, showing a median lead time of five months in detecting MRD progression [2] - The consensus EPS estimate for the upcoming quarterly report is a loss of $0.28 per share, reflecting a year-over-year increase of 56.3%, while revenues are expected to be $13.7 million, down 46.7% from the previous year [3] Market Position - The consensus EPS estimate for Personalis has remained unchanged over the last 30 days, indicating a potential stabilization in earnings expectations [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook in the market [4]

Core Viewpoint - Supernus Pharmaceuticals (SUPN) is identified as a strong momentum stock with a Momentum Style Score of A and a Zacks Rank of 1 (Strong Buy), indicating potential for significant near-term gains [3][4][12]. Momentum Style Analysis - Momentum investing focuses on following a stock's recent price trends, with the aim of capitalizing on established price movements [1]. - The Zacks Momentum Style Score helps investors identify stocks with strong momentum characteristics, addressing the challenges of defining momentum [2]. Performance Metrics - Over the past week, SUPN shares increased by 2.81%, matching the performance of the Zacks Medical - Generic Drugs industry [6]. - In a longer timeframe, SUPN's monthly price change is 7.79%, significantly outperforming the industry's 0.5% [6]. - Over the past quarter, SUPN shares have surged by 51.51%, and over the last year, they have gained 48.49%, while the S&P 500 only increased by 4.67% and 14.71%, respectively [7]. Trading Volume - SUPN's average 20-day trading volume is 808,093 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - Recent earnings estimate revisions for SUPN show one upward revision for the full year, increasing the consensus estimate from $2.05 to $2.25 over the past 60 days [10]. - For the next fiscal year, there has been one upward revision with no downward revisions noted [10]. Conclusion - Given the strong performance metrics and positive earnings outlook, SUPN is positioned as a promising investment opportunity in the near term [12].

Core Viewpoint - Supernus Pharmaceuticals (SUPN) is identified as a strong momentum stock with a Zacks Rank of 1 (Strong Buy) and a Momentum Style Score of B, indicating potential for significant near-term gains [4][12]. Company Performance - SUPN shares have increased by 1.28% over the past week, outperforming the Zacks Medical - Generic Drugs industry, which rose by 0.97% during the same period [6]. - Over the last month, SUPN's stock price has risen by 4.5%, compared to the industry's 1.4% [6]. - In the last quarter, SUPN shares have surged by 46.87%, and over the past year, they have gained 57.31%, significantly outperforming the S&P 500, which increased by 9.31% and 17.01% respectively [7]. Trading Volume - The average 20-day trading volume for SUPN is 645,479 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the past two months, two earnings estimates for SUPN have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from $1.50 to $2.18 [10]. - For the next fiscal year, two estimates have also moved upwards with no downward revisions [10].

Core Viewpoint - Supernus Pharmaceuticals has shown strong stock performance, with a 5.7% increase over the past month and a 29.9% rise since the beginning of the year, outperforming the Zacks Medical sector and the Zacks Medical - Generic Drugs industry [1][2]. Financial Performance - Supernus has consistently exceeded earnings expectations, reporting an EPS of $0.91 against a consensus estimate of $0.47 in its last earnings report [2]. - For the current fiscal year, Supernus is projected to achieve earnings of $2.18 per share on revenues of $696.95 million, reflecting a -30.57% change in EPS and a 5.31% change in revenues. For the next fiscal year, earnings are expected to rise to $2.31 per share on revenues of $843.62 million, indicating a year-over-year change of 5.96% and 21.05%, respectively [3]. Valuation Metrics - Supernus has a Value Score of B, with Growth and Momentum Scores of C, resulting in a combined VGM Score of B. The stock trades at 21.6 times current fiscal year EPS estimates, which is a premium compared to the peer industry average of 8.5 times [5][6]. - On a trailing cash flow basis, Supernus trades at 11.3 times, while the peer group's average is 5.6 times, suggesting that the company is not positioned in the top tier from a value perspective [6]. Zacks Rank - Supernus holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, aligning with the recommendation for investors to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, indicating potential for further stock price appreciation [7].

Core Insights - Assembly Biosciences (ASMB) shares increased by 9.8% to $24.46, following a significant trading volume, contrasting with a 16.4% decline over the past month [1][2] Company Overview - The recent stock price surge is linked to positive investor sentiment regarding Assembly Biosciences' innovative pipeline, which includes four candidates in early-stage studies targeting recurrent genital herpes, Hepatitis B, and Hepatitis D [2] Financial Expectations - The company is projected to report a quarterly loss of $0.50 per share, reflecting a year-over-year increase of 66.9%. Expected revenues are $10.2 million, marking a 49.1% rise from the same quarter last year [3] - The consensus EPS estimate for the upcoming quarter has remained stable over the last 30 days, indicating that stock price movements typically do not sustain without trends in earnings estimate revisions [4] Industry Context - Assembly Biosciences is categorized within the Zacks Medical - Generic Drugs industry, where Doctor Reddy's (RDY) also operates. RDY's stock closed 0.3% higher at $14.87, with a 2.8% return over the past month [4] - Doctor Reddy's has an unchanged consensus EPS estimate of $0.18 for its upcoming report, representing a 350% increase from the previous year [5]

Core Insights - Taysha Gene Therapies, Inc. reported a quarterly loss of $0.09 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.07, marking an earnings surprise of -28.57% [1] - The company generated revenues of $1.99 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 15.73% and showing significant growth from $1.11 million a year ago [2] - Taysha Gene Therapies shares have increased approximately 59.5% year-to-date, outperforming the S&P 500's gain of 8.4% [3] Financial Performance - Over the last four quarters, Taysha Gene Therapies has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $1.73 million, and for the current fiscal year, it is -$0.31 on revenues of $7.51 million [7] Industry Context - The Medical - Generic Drugs industry, to which Taysha Gene Therapies belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - Amphastar Pharmaceuticals reported quarterly earnings of $0.85 per share, exceeding the Zacks Consensus Estimate of $0.71 per share, but down from $0.94 per share a year ago, indicating an earnings surprise of +19.72% [1][2] Financial Performance - The company posted revenues of $174.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 2.69%, but down from $182.39 million year-over-year [2] - Over the last four quarters, Amphastar has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Stock Performance - Amphastar shares have declined approximately 43.9% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.83 for the coming quarter and $3.17 for the current fiscal year [7] - The Zacks Rank for Amphastar is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Amphastar belongs, is currently in the bottom 34% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Viewpoint - Supernus Pharmaceuticals reported strong quarterly earnings, significantly exceeding expectations, which raises questions about future performance and stock outlook [1][2][4]. Financial Performance - Supernus reported earnings of $0.91 per share, surpassing the Zacks Consensus Estimate of $0.47 per share, and showing an increase from $0.36 per share a year ago, resulting in an earnings surprise of +93.62% [1]. - The company posted revenues of $165.45 million for the quarter, exceeding the Zacks Consensus Estimate by 7.34%, although this represents a slight decline from $168.32 million in the same quarter last year [2]. Market Performance - Supernus shares have increased by approximately 2.5% since the beginning of the year, while the S&P 500 has gained 7.6%, indicating underperformance relative to the broader market [3]. Future Outlook - The company's earnings outlook is crucial for assessing future stock performance, with current consensus EPS estimates at $0.52 for the next quarter and $1.89 for the current fiscal year [7]. - The Zacks Rank for Supernus is currently 5 (Strong Sell), suggesting expected underperformance in the near future due to unfavorable estimate revisions prior to the earnings release [6]. Industry Context - The Medical - Generic Drugs industry, to which Supernus belongs, is currently ranked in the bottom 36% of over 250 Zacks industries, indicating potential challenges ahead [8].